MGC Pharma announced it’s received government funding for its clinical trial with the University of Notre Dame Western Australia.
MGC Pharmaceuticals (ASX:MXC) announced on Tuesday (November 12) it’s received funding from the Australian Commonwealth Government for its clinical trial in collaboration with the University of Notre Dame Western Australia.
As quoted in the press release:
First AU$25,000 of the AU$50,000 Grant received
The Grant supports the CogniCann® Phase IIb clinical trial being conducted in collaboration with the University of Notre Dame Western Australia
Securing the Grant demonstrates the Australian Governments’ support for the Company’s stated growing Research & Development agenda, alongside broader continued research into the therapeutic use of phytocannabinoids
The Phase IIb double-blind placebo controlled clinical trial is assessing symptoms associated with dementia and Alzheimer’s disease